Boston Scientific Corporation
BSX
$48.31
-$0.80-1.63%
NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 98.96% | 18.94% | 60.98% | 145.99% | 36.16% |
| Total Depreciation and Amortization | 8.00% | 4.89% | 11.76% | 8.04% | 6.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -295.00% | -21.46% | 231.15% | -120.67% | 103.70% |
| Change in Net Operating Assets | -34.96% | -52.16% | -73.49% | 211.48% | 8.75% |
| Cash from Operations | -35.67% | -6.32% | 34.03% | 58.18% | 229.88% |
| Capital Expenditure | 5.35% | -26.71% | -1.12% | -1.29% | -4.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -118.83% | 97.40% | 77.28% | -2,002.08% | -408.51% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 247.30% | -700.00% | 46.28% | 158.82% | -25.42% |
| Cash from Investing | -18.20% | 86.18% | 64.82% | -315.50% | -75.44% |
| Total Debt Issued | -- | -100.00% | -- | -- | -27.37% |
| Total Debt Repaid | 80.24% | -- | -- | -- | -147.83% |
| Issuance of Common Stock | -29.57% | -28.57% | 19.79% | 23.08% | 43.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 36.43% | 600.00% | 95.51% | -2,800.00% | -1.57% |
| Cash from Financing | -211.59% | -185.98% | -1,585.71% | -1,516.67% | -85.15% |
| Foreign Exchange rate Adjustments | -- | 133.33% | -133.33% | 300.00% | 657.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -261.02% | 132.83% | 277.97% | -131.45% | -78.28% |